Printer Friendly

Court Rules in Favor of Roche Diagnostics in Patent Dispute with Enzo Biochem.

PLEASANTON, Calif. -- Roche Diagnostics today announced that a district judge in New York has ruled in favor of Roche Diagnostics on important aspects of patent infringement allegations brought by Enzo Biochem.

The Court adopted virtually all of the interpretations proposed by Roche Diagnostics and its co-parties relating to seven Enzo patents covered by the order. Judge Sprizzo's ruling followed a week long hearing in July 2005 and extensive legal briefs by the parties.

"This order will allow us to request a further ruling from the Court, declaring that Roche does not infringe on this patent," said Melinda Griffith, Senior Vice President and General Counsel of Roche Molecular Diagnostics, a business unit of Roche Diagnostics. "We look forward to the successful conclusion of this litigation."

The litigation, first filed in 2002, concerns products and techniques for detecting genetic information in biological samples, such as blood.

Among its allegations, Enzo contends that Roche's AmpliChip CYP450 Test infringes Enzo's U.S. Patent No. 4,994,373. However, Judge Sprizzo's order rejected Enzo's interpretations of both the testing format and the "soluble signal" claimed by this patent, and instead agreed with interpretations by Roche Diagnostics and its co-parties.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005, sales by the Pharmaceuticals Division totaled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites and

All trademarks used or mentioned in this release are legally protected by law.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 21, 2006
Previous Article:CF Industries Holdings, Inc. Declares Third Quarter Dividend; Dividend Payable August 31, 2006 To Stockholders Of Record August 14, 2006.
Next Article:Jake Dickson Joins Massini Group as Campaign Manager.

Related Articles
Enzo Biochem Reports Results for Fourth Quarter and Fiscal Year.
Enzo Biochem Awarded Patent Covering Processes for Producing Therapeutic Proteins or RNAs in Living Cells.
Enzo Biochem Reports Court Ruling.
Enzo Biochem Announces Settlement with Sigma-Aldrich in Contract and Patent Litigation.
Enzo Biochem Reports Favorable Markman Ruling in Federal Court Upholding Key Patent Claim Terms.
Enzo Named Senior Party in Interference for Patent on Basic DNA Gel Sequencing Technology.
U.S. Court of Appeals Allows Enzo Biochem Patent Infringement Suit to Proceed.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters